CR20110457A - Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma - Google Patents

Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma

Info

Publication number
CR20110457A
CR20110457A CR20110457A CR20110457A CR20110457A CR 20110457 A CR20110457 A CR 20110457A CR 20110457 A CR20110457 A CR 20110457A CR 20110457 A CR20110457 A CR 20110457A CR 20110457 A CR20110457 A CR 20110457A
Authority
CR
Costa Rica
Prior art keywords
agomelatine
preparation
same
crystal form
new crystal
Prior art date
Application number
CR20110457A
Other languages
English (en)
Inventor
Hanbin Shan
Peng Zhang
Zhedong Yuan
Xudong Jiang
Yu Huang
Hubo Wang
Xufeng Cao
Xingdong Cheng
Xiong Yu
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41370233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110457(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CR20110457A publication Critical patent/CR20110457A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona una nueva forma cristalina de la agomelatina y uso de ésta. el diagrama de difracción de rayos X en polvo de la forma cristalina de la agomelatina muestra picos principales en los ángulos de difracción.
CR20110457A 2009-03-10 2011-08-24 Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma CR20110457A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200910047329.2A CN101585779B (zh) 2009-03-10 2009-03-10 阿戈美拉汀的晶型vi及其制备方法和应用

Publications (1)

Publication Number Publication Date
CR20110457A true CR20110457A (es) 2011-09-21

Family

ID=41370233

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110457A CR20110457A (es) 2009-03-10 2011-08-24 Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma

Country Status (27)

Country Link
US (1) US8614251B2 (es)
EP (1) EP2431355A4 (es)
JP (1) JP2012519715A (es)
KR (1) KR20110123266A (es)
CN (1) CN101585779B (es)
AP (1) AP3049A (es)
AU (1) AU2010223720B2 (es)
BR (1) BRPI1013249A2 (es)
CA (1) CA2754276A1 (es)
CL (1) CL2011002231A1 (es)
CO (1) CO6410293A2 (es)
CR (1) CR20110457A (es)
CU (1) CU20110162A7 (es)
EA (1) EA019127B1 (es)
EC (1) ECSP11011309A (es)
GE (1) GEP20146114B (es)
HN (1) HN2011002408A (es)
IL (1) IL214683A0 (es)
MA (1) MA33100B1 (es)
MX (1) MX2011009339A (es)
NI (1) NI201100167A (es)
PE (1) PE20120653A1 (es)
SG (2) SG173692A1 (es)
TN (1) TN2011000426A1 (es)
UA (1) UA100476C2 (es)
WO (1) WO2010102554A1 (es)
ZA (1) ZA201106049B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN101955440B (zh) * 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
CN102050756A (zh) * 2009-11-09 2011-05-11 北京利乐生制药科技有限公司 阿戈美拉汀新晶型及其制备方法
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102557979B (zh) * 2010-12-16 2014-11-26 北大方正集团有限公司 一种阿戈美拉汀的晶型、其制备方法、用途及药物组合物
WO2012093402A1 (en) * 2011-01-04 2012-07-12 Symed Labs Limited Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
CN102690210A (zh) 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
ES2634243T3 (es) 2011-11-30 2017-09-27 Ratiopharm Gmbh Complejo de agomelatina-urea y formas cristalinas del mismo
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
CN103690499B (zh) * 2013-12-23 2015-05-06 天津泰普药品科技发展有限公司 一种稳定的晶i型阿戈美拉汀片剂及其制备方法
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
EP3075724B1 (en) 2015-03-31 2023-07-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Solid form of agomelatine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2866334B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
FR2923482B1 (fr) 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
EP2319827A1 (en) * 2009-11-09 2011-05-11 Ratiopharm GmbH Process for the production of polymorph form I of agomelatine

Also Published As

Publication number Publication date
UA100476C2 (en) 2012-12-25
PE20120653A1 (es) 2012-06-14
SG173692A1 (en) 2011-09-29
EA201101304A1 (ru) 2012-04-30
JP2012519715A (ja) 2012-08-30
KR20110123266A (ko) 2011-11-14
AP3049A (en) 2014-11-30
AU2010223720A1 (en) 2011-09-08
CO6410293A2 (es) 2012-03-30
AU2010223720B2 (en) 2012-05-03
EP2431355A4 (en) 2012-08-08
TN2011000426A1 (en) 2013-03-27
US20120004313A1 (en) 2012-01-05
CN101585779A (zh) 2009-11-25
US8614251B2 (en) 2013-12-24
GEP20146114B (en) 2014-07-10
ECSP11011309A (es) 2011-10-31
HN2011002408A (es) 2014-06-23
NI201100167A (es) 2012-01-11
WO2010102554A1 (zh) 2010-09-16
CA2754276A1 (en) 2010-09-16
AP2011005914A0 (en) 2011-10-31
ZA201106049B (en) 2012-10-31
IL214683A0 (en) 2011-11-30
BRPI1013249A2 (pt) 2016-04-05
CU20110162A7 (es) 2012-02-15
EP2431355A1 (en) 2012-03-21
MX2011009339A (es) 2011-09-27
MA33100B1 (fr) 2012-03-01
CN101585779B (zh) 2014-04-02
EA019127B1 (ru) 2014-01-30
SG177886A1 (en) 2012-02-28
CL2011002231A1 (es) 2012-02-03

Similar Documents

Publication Publication Date Title
CR20110457A (es) Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
ECSP12012221A (es) Anticuerpos anti-cd40
BR112012002349A2 (pt) composto,e, uso do mesmo
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
EP2666754A4 (en) SYNTHESIS AND USE OF A DOPED VO2 POWDER AND DISPERSANT IN A SINGLE PROCESS
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
SMT201700064B (it) Antagonisti di d2, metodi di sintesi e metodi di uso
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
SMT201400126B (it) Uso di amisulpride per il trattamento di nausea e vomito post-operatori
BR112015002767A2 (pt) composições, métodos, e sistemas para a síntese e uso de agentes de imagiologia
AR082804A1 (es) Formas cristalinas de un inhibidor del factor xa
AR088755A1 (es) Formas solidas de un inhibidor de disociacion transtiretina
BR112013006092A2 (pt) laminado, matéria-prima do laminado, método para preparação de um laminado e uso do laminado
BRPI1007494A2 (pt) composto e uso do mesmo
CO6950501A2 (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso herbicidas iii
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
ES2530578T3 (es) Cristales y cristales reticulados de Proteína A y métodos de uso de los mismos
BR112013014779A2 (pt) composição de filtro solar e uso
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BR112012031967A2 (pt) composto, uso de um composto, combinação de um composto e composição farmacêutica
BRPI1013597A2 (pt) seringa para uso único
ES2641849T3 (es) Compuesto de oxadiazol y procedimiento para su preparación, composición farmacéutica y su uso